News Conference News ESC 2017 ESC Updates Guidelines for Treating STEMI Patients Michael O'Riordan August 27, 2017
News Daily News Evolocumab Not Cost-Effective at Current List Price Michael O'Riordan August 23, 2017
News Daily News TAVR in the US: Regional Variations in Numbers, Outcomes Michael O'Riordan August 22, 2017
News Daily News FDA: Class I Recall for Cook’s Thoracic Endovascular Grafts Michael O'Riordan August 17, 2017
News Daily News FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints Michael O'Riordan August 16, 2017
News Daily News Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests Michael O'Riordan August 14, 2017
News Daily News Many Stroke Patients Stop Statins or Never Start, With Dire Consequences Michael O'Riordan August 02, 2017
News Daily News Boston Scientific Scraps Biodegradable Scaffold Program Michael O'Riordan August 01, 2017
News Daily News FDA Expands CoreValve Indication to Include Intermediate-Risk Patients Michael O'Riordan July 10, 2017
News Conference News TVT 2017 Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base Michael O'Riordan June 17, 2017
News Conference News TVT 2017 Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated Michael O'Riordan June 16, 2017
News Daily News FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement Michael O'Riordan June 06, 2017
News Features Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions Michael O'Riordan May 08, 2017
News Daily News Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes Michael O'Riordan April 27, 2017
News Daily News Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows Michael O'Riordan March 31, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017